RxDoctor Payments Data

Jonas Cooper, MD

Clinical Cardiac Electrophysiology · Chesterfield, MONPI 1154499499

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (38.1%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Baxter Healthcare at 36.5% of the total.

$21,130in general payments, 2019–2025

Across 371 payments — averaging $56.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Baxter Healthcare$8K
  • Boehringer Ingelheim$5K
  • Abbott$3K
  • Boston Scientific$2K
  • Medical Device Business Services, Inc.$737
  • Biosense Webster, Inc.$701
  • plus $3K from 23 others

What the payments were for

  • Consulting fees$7,60536%
  • Speaking & faculty fees$4,69022%
  • Travel & lodging$7373%
  • Food & beverage$8,05838%
  • Education$390%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,130 in reported general payments places this provider in the 60th percentile of 74 clinical cardiac electrophysiology providers in Missouri.

See all clinical cardiac electrophysiology providers in Missouri

Medicare billing

Part B allowed, 2024
$427,016
Medicare patients
1,193
Services billed
7,112

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban496$464,852
XareltoRivaroxaban94$100,580
MultaqDronedarone Hcl29$27,999
Dofetilide54$11,021
Metoprolol Succinate430$5,267
Flecainide Acetate102$4,512
Diltiazem 24hr Er (Cd)Diltiazem Hcl173$4,374
PradaxaDabigatran Etexilate Mesylate19$3,780
Dabigatran EtexilateDabigatran Etexilate Mesylate17$2,785
Propafenone Hcl ErPropafenone Hcl15$2,594
SotalolSotalol Hcl104$2,213
Amiodarone Hcl170$1,850
Nebivolol Hcl24$828
Diltiazem Hcl48$626
Mexiletine Hcl11$566

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$305$464,852496 claims
Johnson & JohnsonXarelto$71$100,58094 claims
Sanofi-aventis U.S. LLCMultaq$340$27,99929 claims
Boehringer IngelheimPradaxa$4,690$3,78019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 74 clinical cardiac electrophysiology providers in Missouri.

Other clinical cardiac electrophysiology in Chesterfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →